Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 18/20 | 0.63 |
| ▸ | CTSK | P43235 | 17/20 | 0.63 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16095226 | 1.00 | CTSS (0.63) | CTSSCTSKCTSLCTSB | |
| SCHEMBL1603288 | 1.00 | CTSS (0.63) | CTSSCTSKCTSLCTSB | |
| SCHEMBL13318956 | 0.92 | CTSS (0.59) | CTSSCTSKCTSLCTSB | |
| SCHEMBL5997785 | 0.92 | CTSS (0.59) | CTSSCTSKCTSLCTSB | |
| SCHEMBL3022636 | 0.92 | CTSS (0.59) | CTSSCTSKCTSLCTSB | |
| SCHEMBL13318958 | 0.92 | CTSS (0.59) | CTSSCTSKCTSLCTSB | |
| SCHEMBL6837916 | 0.87 | CTSK (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL6745774 | 0.87 | CTSK (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL14150791 | 0.87 | CTSK (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL4656416 | 0.87 | CTSK (0.51) | CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113853236-A | Stabilizing peptides of PACAP | 千寿制药株式会社 | 2021-12-28 | — | — | CN | disclosed |
| WO-2020230867-A1 | STABILIZED PACAP PEPTIDE | 千寿製薬株式会社 | 2020-11-19 | — | — | WO | disclosed |
| US-10029956-B2 | Therapies for cancer using isotopically substituted lysine | RETROTOPE, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9840457-B2 | Lysine isotopologues, compositions comprising the same and methods of synthesis | CAMBRIDGE ISOTOPE LABORATORIES, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| EP-2268604-B1 | THERAPIES FOR CANCER USING ISOTOPICALLY SUBSTITUTED LYSINE | RETROTOPE INC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20160016890-A1 | LYSINE ISOTOPOLOGUES, COMPOSITIONS COMPRISING THE SAME AND METHODS OF SYNTHESIS | CAMBRIDGE ISOTOPE LABORATORIES, INC. | 2016-01-21 | — | — | US | disclosed |
| WO-2014150909-A1 | LYSINE ISOTOPOLOGUES, COMPOSITIONS COMPRISING THE SAME AND METHODS OF SYNTHESIS | CAMBRIDGE ISOTOPE LABORATORIES, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20110082208-A1 | THERAPIES FOR CANCER USING ISOTOPICALLY SUBSTITUTED LYSINE | BIOJIVA LLC | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082208-A1 | THERAPIES FOR CANCER USING ISOTOPICALLY SUBSTITUTED LYSINE | AADAT, DOT1L, TP53 | CTSS 493/4885CTSK 174/4885CTSL 416/4885 |
| US-20160016890-A1 | LYSINE ISOTOPOLOGUES, COMPOSITIONS COMPRISING THE SAME AND METHODS OF SYNTHESIS | PLOD1, PHYKPL, AADAT | CTSS 2046/4885CTSK 785/4885CTSL 2132/4885 |
| US-10029956-B2 | Therapies for cancer using isotopically substituted lysine | AADAT, DOT1L, TP53 | CTSS 493/4885CTSK 174/4885CTSL 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.